Navigation Links
Trubion Pharmaceuticals to Present at Upcoming Investor Conferences
Date:9/4/2007

Dr. Peter Thompson to Present at BioCentury's Newsmakers in the Biotech Industry, Bank of America Investment, and UBS Global Life Sciences Investor

Conferences

SEATTLE, Sept. 4 /PRNewswire-FirstCall/ -- Trubion Pharmaceuticals, Inc. (Nasdaq: TRBN) announced today that Dr. Peter Thompson, president, chief executive officer, and chairman of Trubion, will present an overview of the company at three September investor conferences:

-- BioCentury's NewsMakers in the Biotech Industry conference at the

Millennium Broadway Hotel & Conference Center, 145 W. 44th St., New

York. Dr. Thompson is scheduled to present on Thursday, Sept. 6. A

webcast of the presentation will be available at http://www.corporate-ir.net/ireye/confLobby.zhtml?ticker=TRBN&item_id=16304 70.

-- Bank of America 37th Annual Investment Conference at the Ritz-Carlton,

600 Stockton St. (at California St.), San Francisco. Dr. Thompson is

scheduled to present on Monday, Sept. 17. A webcast of the presentation

will be available at

http://www.veracast.com/webcasts/bas/37th-annual-2007/id22113469.cfm.

-- UBS Global Life Sciences Investor Conference at the Grand Hyatt, 109 E.

42nd St. (at Grand Central Station), New York. Dr. Thompson is

scheduled to present on Monday, Sept. 24. A webcast of the presentation

will be available at

http://events.streamx.us/us/event/eventdetails.aspx?id=ubs20070924.

About Trubion

Trubion is a biopharmaceutical company creating a pipeline of product candidates to treat autoimmune disease and cancer. The company's product candidates are novel proteins known as single-chain polypeptides and are designed using its SMIP(TM) custom drug assembly technology. In less than 24 months the Company designed, developed and submitted to the FDA an Investigational New Drug application for, its lead product candidate, TRU-015, which has completed a Phase IIb clinical trial for the treatment of rheumatoid arthritis. In December 2005, the company entered into a collaboration agreement with Wyeth for the development and worldwide commercialization of certain therapeutics, including TRU-015. In addition, Trubion's TRU-016 program targets CD37, an antigen present on B cells, for the treatment of non-Hodgkin's lymphoma and chronic lymphocytic leukemia. Subject to satisfactory completion of preclinical testing of TRU-016, the company expects to file an IND for TRU-016 in the second half of 2007. Trubion currently retains all development and commercialization rights for the TRU-016 program. For additional information visit http://www.trubion.com.


'/>"/>
SOURCE Trubion Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Deltanoid Pharmaceuticals begins phase II osteoporosis study
2. The Coming of Biotech Generic Pharmaceuticals
3. Amplification of genome-representative DNA from limited sources with GenomePlex WGA technology for use in genetic alterations studies
4. Wisconsin firms to present at Cleantech venture capital event
5. New Sonic Foundry search engine finds words, phrases in video presentations
6. Lone Wisconsin firm to present at InvestMidwest
7. Sonic Foundry creates search engine for 7,000 expert video presentations
8. InvestMidWest calls for business presentations
9. Wicab to present BrainPort at Boston conference
10. Three more Wisconsin firms to present at venture forum
11. Six Wisconsin firms to present at BIO Mid-America VentureForum
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... , Jan. 19, 2017  ArmaGen, Inc., today ... , Ph.D., as chief executive officer, as well ... Dr. Schmidt brings to ArmaGen more than 17 years ... and development of biotherapeutics and pharmaceuticals. ... the diverse experience and skillset necessary to lead ...
(Date:1/19/2017)... ... 2017 , ... The American Medical Informatics Association (AMIA) today ... Policy. Specifically, the nation’s leading informatics experts, said data sharing plans should be ... recommended that NIH earmark funding for researchers to produce and execute data sharing ...
(Date:1/19/2017)... ... , ... FireflySci Inc. is a go-getter type of company that continues to ... two main factors. The first is the amazing customer service that the FireflySci ... all around the world. , 2016 was a tremendous sales year for FFS and ...
(Date:1/19/2017)... YORK , Jan. 18, 2017 ... to reach USD 92.9 billion by 2025, according ... Inc. Pharmaceutical industry has been adaptive of the ... as early as 2002. Among the services outsourced, ... forerunners. For instance, Johnson & Johnson was the ...
Breaking Biology Technology:
(Date:12/8/2016)... 8, 2016  Singulex, Inc., the leader in Next ... into a license and supply agreement with Thermo Fisher ... provides Singulex access to Thermo Scientific BRAHMS PCT (Procalcitonin), ... is used to diagnose systemic bacterial infection and sepsis ... to aid in assessing the risk of critically ill ...
(Date:12/7/2016)... December 7, 2016 BioCatch , the global ... its patent portfolio, which grew to over 40 granted and pending patents. ... , , ... patent entitled " System, Device, and Method Estimating Force Applied ... device makers to forego costly hardware components needed to estimate the force ...
(Date:12/7/2016)... BOSTON , Dec. 7, 2016   ... today announced the appointment of new CEO ... industry executive with decades of experience, has served ... and Cisco, where he specialized in expanding a ... emerging technology portfolios. He most recently served as ...
Breaking Biology News(10 mins):